Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
100.32%
-
Total 13F principal
-
$239,416,100
-
Principal change
-
-$17,857,249
-
Total reported market value
-
$244,284,801
-
Number of holders
-
21
-
Value change
-
-$22,593,875
-
Number of buys
-
9
-
Number of sells
-
9
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q2 2022
As of 30 Jun 2022,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
21 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$239,416,100
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, Polar Asset Management Partners Inc., D. E. Shaw & Co., Inc., LAZARD ASSET MANAGEMENT LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, BlackRock Inc., CITIGROUP INC, AVIVA PLC, and Point72 Asset Management, L.P..
This page lists
21
institutional bondholders reporting positions
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.